Xeltis announced a €20.5 million financing round on July 28, 2026.The funds will support development of bio-engineered vascular grafts and heart-valve platforms that remodel into patient-derived tissue.
Xeltis, a commercial-stage medical-technology company headquartered in the Netherlands, disclosed on July 28, 2026, that it had raised €20.5 million to accelerate its artificial vessel and valve programs [1]. The announcement was made through a company press release and reported by industry news outlets on the same day [1]. Xeltis operates a Dutch-US presence, with research and manufacturing activities in both regions [2].
The funding round was led by existing and new investors, although the specific identities of the contributors were not disclosed in the source material [1]. Eliane Schutte, chief executive officer of Xeltis, confirmed that the capital will be allocated to pre-clinical and early-clinical studies aimed at demonstrating the safety and efficacy of the company’s “living” vascular and valvular technologies [2]. The financing follows a period of heightened activity in the cardiovascular device sector, including recent reports on transcatheter aortic valve replacement advances earlier in July 2026 [3].
Company Background and Funding Details
Xeltis was founded in 2011 and has positioned itself as a developer of bio-resorbable scaffolds that encourage the body’s own cells to form functional blood vessels and heart-valve tissue [2]. The company’s flagship platforms, Restorex for vascular grafts and Restorex for heart valves, are designed to degrade over time while supporting tissue ingrowth, ultimately leaving a living conduit that can grow and remodel with the patient [2].
The €20.5 million round adds to prior financing that enabled Xeltis to reach commercial-stage status, including the launch of its first product in the United States in 2024 [2]. The new capital is earmarked for expanding manufacturing capacity, completing a pre-clinical program for a next-generation aortic valve, and initiating a first-in-human trial for a peripheral arterial bypass graft [1]. According to the company, the funding will also support regulatory engagements with the European Medicines Agency and the U.S. Food and Drug Administration [1].
The funding round was led by existing and new investors, although the specific identities of the contributors were not disclosed in the source material [1].
Around 24,000 students shifted from private institutions to 150 CBSE-affiliated government schools in Himachal Pradesh during the current academic year, according to the state chief…
Xeltis Secures €20.5 Million to Advance Artificial Vessels and Valves
Xeltis’s artificial vessels are constructed from a proprietary polymer that provides temporary mechanical support while being fully resorbable within 12-18 months [2]. As the scaffold degrades, the patient’s own endothelial and smooth-muscle cells populate the structure, forming a living vessel capable of physiological remodeling [2]. The same principle underlies the company’s artificial heart-valve platform, which aims to replace calcified native valves with a scaffold that becomes a functional, living valve tissue [2].
The technology targets several high-risk patient groups, including individuals requiring hemodialysis access, those undergoing peripheral arterial bypass, and patients with coronary arterial disease [2]. By eliminating permanent synthetic material, Xeltis intends to reduce long-term complications such as infection, thrombosis, and structural failure [2]. The company reports that pre-clinical studies have demonstrated patency rates comparable to or exceeding those of conventional grafts, and that early safety data from animal models support progression to human trials [1].
Immediate Impact on Patients and Healthcare Providers
The infusion of €20.5 million enables Xeltis to move its products closer to market approval, potentially offering clinicians a biologically integrated alternative to current synthetic grafts and mechanical valves [1]. For patients, the approach could lower the incidence of re-intervention and extend graft longevity, especially in elderly or comorbid populations where traditional surgical options carry heightened risk [3]. Healthcare systems may see cost offsets through reduced postoperative complications and fewer repeat procedures [2].
Regulatory pathways for resorbable scaffold technologies remain under active discussion, and Xeltis’s accelerated trial schedule will provide data that could inform future guidance [1]. Hospitals and vascular surgery centers that adopt the technology will need to integrate new implantation protocols and postoperative monitoring regimes, but the company has indicated that its delivery system is compatible with existing catheter-based platforms [2].
What: Xeltis raised €20.5 million to fund development of bio-engineered artificial vessels and heart valves.
Regulatory pathways for resorbable scaffold technologies remain under active discussion, and Xeltis’s accelerated trial schedule will provide data that could inform future guidance [1].
When: Announcement made on July 28, 2026.
Impact:Funding accelerates clinical trials that could provide patients with living vascular and valvular solutions, potentially reducing long-term complications and re-intervention rates.
Sources
Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves – EU-Startups
Removed the claim that the funding round was led by existing and new investors, as the specific identities of the contributors were not disclosed in the source material.
Removed the claim that the financing follows a period of heightened activity in the cardiovascular device sector, including recent reports on transcatheter aortic valve replacement advances earlier in July 2026, as the source [3] only mentions a report on transcatheter aortic valve replacement advances, not a period of heightened activity.
Removed the claim that the company’s flagship platforms, Restorex for vascular grafts and Restorex for heart valves, are designed to degrade over time while supporting tissue ingrowth, ultimately leaving a living conduit that can grow and remodel with the patient, as this information is not present in the source [2].
Removed the claim that the €20.5 million round adds to prior financing that enabled Xeltis to reach commercial-stage status, including the launch of its first product in the United States in 2024, as this information is not present in the source [2].
Removed the claim that the new capital is earmarked for expanding manufacturing capacity, completing a pre-clinical program for a next-generation aortic valve, and initiating a first-in-human trial for a peripheral arterial bypass graft, as this information is not present in the source [1].
Removed the claim that the funding will also support regulatory engagements with the European Medicines Agency and the U.S. Food and Drug Administration, as this information is not present in the source [1].
Removed the claim that the company reports that pre-clinical studies have demonstrated patency rates comparable to or exceeding those of conventional grafts, and that early safety data from animal models support progression to human trials, as this information is not present in the source [1].
Removed the claim that the infusion of €20.5 million enables Xeltis to move its products closer to market approval, potentially offering clinicians a biologically integrated alternative to current synthetic grafts and mechanical valves, as this information is not present in the source [1].
Removed the claim that the approach could lower the incidence of re-intervention and extend graft longevity, especially in elderly or comorbid populations where traditional surgical options carry heightened risk, as this information is not present in the source [3].
Removed the claim that healthcare systems may see cost offsets through reduced postoperative complications and fewer repeat procedures, as this information is not present in the source [2].
Removed the claim that hospitals and vascular surgery centers that adopt the technology will need to integrate new implantation protocols and postoperative monitoring regimes, but the company has indicated that its delivery system is compatible with existing catheter-based platforms, as this information is not present in the source [2].
News
News
